Top

Published in:

01-06-2018 | Original Article

Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle

Authors: Argerie Tsimicalis, Madalina Boitor, Catherine E. Ferland, Frank Rauch, Sylvie Le May, Jaimie Isabel Carrier, Tracy Ngheim, Claudette Bilodeau

Published in: European Journal of Pediatrics | Issue 6/2018

Abstract

The objective was to describe the pain and quality of life among children and adolescents with any osteogenesis imperfecta (OI) type over one intravenous bisphosphonate treatment cycle from a child and parental perspective. A prospective, observational study was conducted, where children and adolescents evaluated their pain intensity, location, and quality, as well as quality of life before, 1 week after treatment, and 6 months later. Quality of life was also evaluated from the parental perspective at the same three time points. Thirty-three child/parent dyads participated. The results showed that pain intensity on the 0–10 self-report scale after the Zoledronate infusion (median = 0, range = 0–6) was not different from pre (median = 2, range = 0–10) and 6-months post-scores (median = 2, range = 0–8) (p = 0.170). Children and adolescents with OI reported experiencing pain mainly in the ankles and the anterior and posterior shoulders. They selected evaluative pain descriptors such as uncomfortable (n = 16, 48%) and annoying (n = 13, 39%). Children and adolescents’ functioning and quality of life did not change significantly across the bisphosphonate treatment cycle (p = 0.326), parents perceived an improvement immediately after the treatment compared to before (p = 0.016).

Conclusion: Children and adolescents with OI experience mild, yet complex pain localized across several body areas. There is little fluctuation in the pain intensity and functioning of children with OI undergoing bisphosphonate treatment.

What is Known:

• Acute and chronic musculoskeletal pain remains a major issue in OI.

• Pain has a negative impact on quality of life.

What is New:

• New and unpublished methods and findings describing the pain and quality of life of children and adolescents with OI over one intravenous bisphosphonate treatment cycle from a child- and parental-proxy perspective.

• Children and adolescents with OI experience pain intensity that is mild, yet complex in quality and localized across several body areas.

Al-Harthy M, Ohrbach R, Michelotti A, List T (2016) The effect of culture on pain sensitivity. J Oral Rehabil 43(2):81–88. https://doi.org/10.1111/joor.12346 CrossRefPubMed

Arponen H, Makitie O, Waltimo-Siren J (2014) Association between joint hypermobility, scoliosis, and cranial base anomalies in paediatric Osteogenesis imperfecta patients: a retrospective cross-sectional study. BMC Musculoskelet Disord 15:428CrossRefPubMedPubMedCentral

Bishop N, Harrison R, Ahmed F, Shaw N, Eastell R, Campbell M, Knowles E, Hill C, Hall C, Chapman S, Sprigg A, Rigby A (2010) A randomized, controlled dose-ranging study of Risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25(1):32–40. https://doi.org/10.1359/jbmr.090712 CrossRefPubMed

Bishop N, Adami S, Ahmed SF, Anton J, Arundel P, Burren CP, Devogelaer JP, Hangartner T, Hosszu E, Lane JM, Lorenc R, Makitie O, Munns CF, Paredes A, Pavlov H, Plotkin H, Raggio CL, Reyes ML, Schoenau E, Semler O, Sillence DO, Steiner RD (2013) Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial. Lancet 382(9902):1424–1432. https://doi.org/10.1016/S0140-6736(13)61091-0 CrossRefPubMed

Chevrel G, Schott AM, Fontanges E, Charrin JE, Lina-Granade G, Duboeuf F, Garnero P, Arlot M, Raynal C, Meunier PJ (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21(2):300–306. https://doi.org/10.1359/Jbmr.051015 CrossRefPubMed

Corli O, Martoni AA, Porcu L, Roberto A, Pinto C, Torri V, Guglieri I, Zagonel V, Oncology ESP (2016) Non-clinical factors influencing pain intensity in cancer patients: socio-cultural-economic status, awareness of disease and the relation with the oncologist. Eur J Intern Med 33:E18–E19. https://doi.org/10.1016/j.ejim.2016.04.019 CrossRefPubMed

Dahan-Oliel N, Oliel S, Tsimicalis A, Montpetit K, Rauch F, Dogba MJ (2016) Quality of life in osteogenesis imperfecta: a mixed-methods systematic review. Am J Med Genet A 170(1):62–76. https://doi.org/10.1002/ajmg.a.37377 CrossRef

Dogba MJ, Rauch F, Tre G, Glorieux FH, Bedos C (2014) Shaping and managing the course of a child's disease: parental experiences with osteogenesis imperfecta. Disabil Health J 7(3):343–349. https://doi.org/10.1016/j.dhjo.2014.03.002 CrossRefPubMed

Dwan K, Phillipi CA, Steiner RD, Basel D (2016) Bisphosphonate therapy for osteogenesis imperfecta. The Cochrane database of systematic reviews 10:CD005088. https://doi.org/10.1002/14651858.CD005088.pub4 PubMedCrossRef

10.

Eccleston C, Palermo TM, Williams AC, Lewandowski Holley A, Morley S, Fisher E, Law E (2014) Psychological therapies for the management of chronic and recurrent pain in children and adolescents. Cochrane Database of Syst Rev 5:CD003968. https://doi.org/10.1002/14651858.CD003968.pub4 CrossRef

11.

Eiser C, Varni JW (2013) Health-related quality of life and symptom reporting: similarities and differences between children and their parents. Eur J Pediatr 172(10):1299–1304. https://doi.org/10.1007/s00431-013-2049-9 CrossRefPubMed

12.

Fernandes AM, De Campos C, Batalha L, Perdigao A, Jacob E (2014) Pain assessment using the adolescent pediatric pain tool: a systematic review. Pain Res Manag 19(4):212–218CrossRefPubMedPubMedCentral

13.

Finan PH, Goodin BR, Smith MT (2013) The Association of Sleep and Pain: an update and a path forward. J Pain 14(12):1539–1552. https://doi.org/10.1016/j.jpain.2013.08.007 CrossRefPubMedPubMedCentral

14.

Food Drug Aadministration. Center for Drug Evaluation and Research. Statistical review and evaluation - clinical studies: Zometa (zoledronic acid) intravenous injection (i.v.) 4 mg lyophilized powder. Treatment of children with osteogenesis imperfecta (OI). http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm072901.pdf

15.

Forlino A, Marini JC (2016) Osteogenesis imperfecta. Lancet 387(10028):1657–1671. https://doi.org/10.1016/S0140-6736(15)00728-X CrossRefPubMed

16.

Goesling J, Clauw DJ, Hassett AL (2013) Pain and depression: an integrative review of neurobiological and psychological factors. Curr Psychiat Rep 15(12):Artn 421. https://doi.org/10.1007/S11920-013-0421-0 CrossRef

17.

Harrington J, Sochett E, Howard A (2014) Update on the evaluation and treatment of osteogenesis imperfecta. Pediatr Clin N Am 61(6):1243–1257. https://doi.org/10.1016/j.pc1.2014.08.010 CrossRef

18.

Hill CL, Baird WO, Walters SJ (2014) Quality of life in children and adolescents with osteogenesis imperfecta: a qualitative interview based study. Health Qual Life Out 12:54. https://doi.org/10.1186/1477-7525-12-54 CrossRef

19.

Jacob E, Mack AK, Savedra M, Van Cleve L, Wilkie DJ (2014) Adolescent pediatric pain tool for multidimensional measurement of pain in children and adolescents. Pain Manag Nurs 15(3):694–706. https://doi.org/10.1016/j.pmn.2013.03.002 CrossRefPubMed

20.

Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, Chernoff EJ, Hill SC, Gerber LH, Marini JC (2005) Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement. J Bone Miner Res 20(6):977–986. https://doi.org/10.1359/JBMR.050109 CrossRefPubMed

21.

Martin E, Shapiro JR (2007) Osteogenesis imperfecta: epidemiology and pathophysiology. Current Osteoporosis Reports 5(3):91–97CrossRefPubMed

22.

McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, Eccleston C, Finley GA, Goldschneider K, Haverkos L, Hertz SH, Ljungman G, Palermo T, Rappaport BA, Rhodes T, Schechter N, Scott J, Sethna N, Svensson OK, Stinson J, von Baeyer CL, Walker L, Weisman S, White RE, Zajicek A, Zeltzer L, PedImmpact (2008) Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain : Off J Am Pain Soc 9(9):771–783. https://doi.org/10.1016/j.jpain.2008.04.007 CrossRef

23.

McKiernan FE (2005) Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 16(12):1698–1702. https://doi.org/10.1007/s00198-005-1905-5 CrossRef

24.

Merskey H, Bogduk N, International Association for the Study of Pain. Task Force on Taxonomy (1994) Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. IASP press

25.

Nghiem T, Louli J, Treherne SC, Anderson CE, Tsimicalis A, Lalloo C, Stinson JN, Thorstad K (2017) Pain experiences of children and adolescents with osteogenesis imperfecta an integrative review. Clin J Pain 33(3):271–280. https://doi.org/10.1097/Ajp.0000000000000395 PubMedCrossRef

26.

Palermo TM, Chambers CT (2005) Parent and family factors in pediatric chronic pain and disability: an integrative approach. Pain 119(1–3):1–4. https://doi.org/10.1016/j.pain.2005.10.027 CrossRefPubMed

27.

Palermo TM, Eccleston C (2009) Parents of children and adolescents with chronic pain. Pain 146(1–2):15–17. https://doi.org/10.1016/j.pain.2009.05.009 CrossRefPubMedPubMedCentral

28.

Rahim-Williams B, Riley JL 3rd, Williams AK, Fillingim RB (2012) A quantitative review of ethnic group differences in experimental pain response: do biology, psychology, and culture matter? Pain Med 13(4):522–540. https://doi.org/10.1111/j.1526-4637.2012.01336.x CrossRefPubMedPubMedCentral

29.

Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24(7):1282–1289. https://doi.org/10.1359/jbmr.090213 CrossRefPubMed

30.

Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C (2004) Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study. Lancet 363(9419):1427–1431. https://doi.org/10.1016/S0140-6736(04)16101-1 CrossRefPubMed

31.

Savedra MC, Tesler MD, Holzemer WL, Brokaw P (1995) A strategy to assess the temporal dimension of pain in children and adolescents. Nurs Res 44(5):272-276CrossRef

32.

Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, Herring JA (2005) Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 25(6):786–791CrossRefPubMed

33.

Stinson JN, Kavanagh T, Yamada J, Gill N, Stevens B (2006) Systematic review of the psychometric properties, interpretability and feasibility of self-report pain intensity measures for use in clinical trials in children and adolescents. Pain 125(1–2):143–157. https://doi.org/10.1016/j.pain.2006.05.006 CrossRefPubMed

34.

Stinson JN, Jibb LA, Nguyen C, Nathan PC, Maloney AM, Dupuis LL, Gerstle JT, Alman B, Hopyan S, Strahlendorf C, Portwine C, Johnston DL, Orr M (2013) Development and testing of a multidimensional iPhone pain assessment application for adolescents with cancer. J Med Internet Res 15(3):e51. https://doi.org/10.2196/jmir.2350 CrossRefPubMedPubMedCentral

35.

Tessier S, Vuillemin A, Lemelle JL, Briancon S (2009) Psychometric properties of the French pediatric quality of life inventory version 4.0 (PedsQL (TM) 4.0) generic core scales. Eur Rev Appl Psychol 59(4):291–300. https://doi.org/10.1016/j.erap.2009.06.001 CrossRef

36.

Trejo P, Rauch F (2016) Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment. Osteoporosis Int 27(12):3427–3437. https://doi.org/10.1007/s00198-016-3723-3 CrossRef

37.

Tsimicalis A, Denis-Larocque G, Michalovic A, Lepage C, Williams K, Yao TR, Palomo T, Dahan-Oliel N, Le May S, Rauch F (2016) The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review. Qual Life Res 25(8):1877–1896. https://doi.org/10.1007/s11136-016-1247-0 CrossRefPubMed

38.

Van Dijk FS, Sillence DO (2014) Osteogenesis imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet 164A(6):1470–1481. https://doi.org/10.1002/ajmg.a.36545 CrossRefPubMed

39.

Varni JW, Seid M, Kurtin PS (2001) PedsQL (TM) 4.0: reliability and validity of the pediatric quality of life inventory (TM) version 4.0 generic core scales in healthy and patient populations. Med Care 39(8):800–812. https://doi.org/10.1097/00005650-200108000-00006 CrossRefPubMed

40.

Varni JW, Seid M, Knight TS, Burwinkle T, Brown J, Szer IS (2002) The PedsQL (TM) in pediatric rheumatology—reliability, validity, and responsiveness of the pediatric quality of life inventory (TM) generic core scales and rheumatology module. Arthritis Rheum 46(3):714–725. https://doi.org/10.1002/art.10095 CrossRefPubMed

41.

Vyskocil V, Pikner R, Kutilek T (2005) Effect of alendronate therapy in children with osteogenesis imperfecta. Joint Bone Spine 72(5):416–423. https://doi.org/10.1016/j.jbspin.2004.09.005 CrossRefPubMed

42.

Ward LM, Rauch F, Whyte MP, D'Astous J, Gates PE, Grogan D, Lester EL, McCall RE, Pressly TA, Sanders JO, Smith PA, Steiner RD, Sullivan E, Tyerman G, Smith-Wright DL, Verbruggen N, Heyden N, Lombardi A, Glorieux FH (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocr Metab 96(2):355–364. https://doi.org/10.1210/jc.2010-0636 CrossRefPubMed

43.

Wilkie DJ, Holzemer WL, Tesler MD, Ward JA, Paul SM, Savedra MC (1990) Measuring pain quality: validity and reliability of children's and adolescents' pain language. Pain 41(2):151–159CrossRefPubMed

44.

Wood C, von Baeyer CL, Bourrillon A, Dejos-Conant V, Clyti N, Abitbol V (2004) Self-assessment of immediate post-vaccination pain after two different MMR vaccines administered as a second dose in 4- to 6-year-old children. Vaccine 23(2):127–131. https://doi.org/10.1016/j.vaccine.2004.08.029 CrossRefPubMed

45.

World Health Organization (2012) WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses. 1. World Health Organization,

46.

Zack P, Franck L, Devile C, Clark C (2005) Fracture and non-fracture pain in children with osteogenesis imperfecta. Acta Paediatr 94(9):1238–1242. https://doi.org/10.1080/08035250510028722 CrossRefPubMed

Title: Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle
Authors: Argerie Tsimicalis
Madalina Boitor
Catherine E. Ferland
Frank Rauch
Sylvie Le May
Jaimie Isabel Carrier
Tracy Ngheim
Claudette Bilodeau
Publication date: 01-06-2018
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Pediatrics / Issue 6/2018
Print ISSN: 0340-6199
Electronic ISSN: 1432-1076
DOI: https://doi.org/10.1007/s00431-018-3127-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Pain and quality of life of children and adolescents with osteogenesis imperfecta over a bisphosphonate treatment cycle

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2018

Development of a core set of quality indicators for paediatric primary care practices in Europe, COSI-PPC-EU

Prevalence of overweight/obesity among 7-year-old children—WHO Childhood Obesity Surveillance Initiative in Slovakia, trends and differences between selected European countries

Diagnostic characteristics of anterior cutaneous nerve entrapment syndrome in childhood

Characteristics of children admitted to intensive care with acute bronchiolitis

Eyelash length for the diagnosis of atopic dermatitis and ichthyosis vulgaris in children—a case control study

Performance and skill retention of five supraglottic airway devices for the pediatric difficult airway in a manikin